Drug intelligence / Profile preview

TTP607

Development stage: Phase 1
Lead developer: vTv Therapeutics
Modality: Small Molecules
Administration: Intravenous (via Central Venous Catheter)

Overview

TTP607 is a small-molecule pan-Aurora kinase inhibitor developed for its potential antineoplastic (anticancer) activity. It selectively binds to and inhibits Aurora kinases, a family of serine/threonine-protein kinases that play critical roles in the regulation of mitosis. By blocking these enzymes, TTP607 disrupts abnormal cell division and proliferation, potentially leading to cancer cell death. The drug was investigated primarily for use in solid tumors and lymphoma but did not advance beyond early clinical development[1][4][5].

Other names: TTP607TTP-607TTP 607HPP-607HPP607HPP 607TTP-9607TTP9607TTP 9607

Targets

AURK (Aurora kinase family)

Beyond the preview

Go deeper on TTP607.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TTP607.

Explore the full profile